Discovery points to innovative new way to treat Duchenne muscular dystrophy

DiscoveryPointsToInnovativeNewWayToTreatDuchenneMuscularDystrophy
Researchers have discovered a new way to treat the loss of muscle function caused by Duchenne muscular dystrophy in animal models of the disease

Original source: Ottawa Hospital Research Institute

Researchers at The Ottawa Hospital and the University of Ottawa have discovered a new way to treat the loss of muscle function caused by Duchenne muscular dystrophy in animal models of the disease. As reported in Cell Stem Cell, the team restored muscle stem cell function that is impaired in Duchenne muscular dystophy, resulting in efficient regeneration of the muscle and preventing the progressive loss of muscle strength characteristic of the disease.

“This is a huge step forward in developing a new approach for treating Duchenne muscular dystrophy,” said Dr. Michael Rudnicki, senior scientist and Director of the Regenerative Medicine Program at The Ottawa Hospital and a professor at the University of Ottawa. “We were able to preserve the muscle strength and function that are usually lost over time in this disease.”

Duchenne muscular dystrophy is an inherited disease that weakens the muscles and causes death by the second or third decade of life. About one in 3,600 boys live with this condition, and there is no cure.

Dr. Rudnicki’s team previously made the landmark discovery that Duchenne muscular dystrophy affects muscle stem cells, not just the muscle fibers. Muscle stem cells are responsible for repairing muscle fibers after injury and exercise. In people with Duchenne muscular dystrophy, their stem cells do not produce enough of the cells that will become muscle cells. This is because they are missing a protein called dystrophin, which properly orients the cell division needed to form new muscle cells.

The team found that activating a protein called epidermal growth factor receptor (EGFR) could restore this pathway and create new muscle cells, without the need for dystrophin.

The researchers inserted a gene that produced a steady supply of EGF into the muscle of a mouse model of Duchenne muscular dystrophy before symptoms of the disease began. After one month, the treated mice had 18 percent more muscle mass and less muscle scarring than untreated controls. The treated mice also had 30 percent more muscle fibers, and the muscles generated 32 percent more force compared to untreated mice. Muscle function was restored to almost normal levels.

This proof-of-concept study shows that the muscle repair pathway in Duchenne muscular dystrophy is correctable. However, EGF would not be a practical treatment because the protein cannot travel from the bloodstream into the muscles. The researchers’ next step is to find a small-molecule drug that triggers this same pathway and can be easily delivered through the bloodstream. They will also look at the long-term effects of triggering this pathway, as the therapy would likely be taken throughout life.

“Duchenne muscular dystrophy is complex, and we will probably need a combination of treatments to address all aspects of the disease,” said Dr. Rudnicki.